Pioneering Patient Care: Exploring Innovations and Market Trends in Controlled Release Drug Delivery Market

The controlled release drug delivery market size has grown rapidly in recent years. It will grow from $59.2 billion in 2023 to $66.18 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to pioneering drug delivery systems, early polymer-based formulations, introduction of microencapsulation techniques, emergence of transdermal delivery, regulatory approvals and standardization..

The controlled release drug delivery market size is expected to see rapid growth in the next few years. It will grow to $105.06 billion in 2028 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to shift towards personalized medicine, technological integration for patient convenience, expansion of biologics and biosimilars, market expansion in developing regions, advancements in polymer science.. Major trends in the forecast period include biodegradable and biocompatible materials, nanotechnology advancements, personalized medicine and targeted therapies, advances in implantable devices, innovative encapsulation techniques..

Market Overview -
Controlled release drug delivery refers to a dosage form that administers a medicine or medication in a specified way. This drug delivery method continuously delivers pharmaceuticals or medications in predictable kinetics for the predetermined time.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=9930&type=smp

Controlled-Release Drug Delivery Market Surges As Chronic Diseases Become Global Health Priority
The rising prevalence of chronic diseases is expected to propel the growth of the controlled release drug delivery market. Chronic diseases are also known as noncommunicable diseases. It refers to conditions such as heart disease, cancer, and diabetes diseases lasting more than a year and requiring continuing medical care, limiting everyday activities, or both. Controlled-release drug delivery is crucial for treating chronic diseases. For patients with chronic illnesses that require years of treatment or those who reside in areas with limited resources and access to healthcare, drug delivery formulations that allow prolonged medication release are essential. For instance, in September 2022, according to report shared by the World Health Organization (WHO), a Switzerland-based health-specialized agency, every year, 41 million people die from chronic diseases, which accounts for 74 percent of all fatalities worldwide. Before the age of 70, 17 million individuals lose their lives to chronic illnesses. Moreover, 77 percent of deaths from chronic diseases occur in low- and middle-income nations. And these numbers are expected to rise in the future. Therefore, the rising prevalence of chronic diseases is driving the growth of the controlled release drug delivery market.

Competitive Landscape -
Major companies operating in the controlled release drug delivery market report are Johnson & Johnson Services Inc., Merck & Co. Inc., Alkermes plc, Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel LLC, GlaxoSmithKline plc, Bayer Healthcare LLC, Collegium Pharmaceuticals Inc., GE HealthCare Technologies Inc., Adare Pharmaceuticals Inc., Allergan plc, Novartis AG, Lonza Group AG, Colorcon Inc., SKY Pharmaceuticals Pvt. Ltd., AstraZeneca plc, Biogen Inc., Orbis Biosciences Inc., Alza Corporation, MicroCHIPS Inc., Endo International plc, Heron Therapeutics Inc., Intellipharmaceutics International Inc., Ipsen Biopharmaceuticals Inc., Luye Pharma Group Ltd., Medtronic plc, Nektar Therapeutics, Novo Nordisk A/S, Ocular Therapeutix Inc., Pacira BioSciences Inc., Progenity Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., Vectura Group plc, West Pharmaceutical Services Inc., Zosano Pharma Corporation, Zynerba Pharmaceuticals Inc. .

Evonik Industries Ag Unveils Groundbreaking Microparticle Technology, Udratec Soluflow, Revolutionizing Controlled-Release Drug Delivery
Technological advancement is a key trend gaining popularity in the controlled-release drug delivery market. Major companies operating in the controlled-release drug delivery market are adopting new technologies to sustain their position in the market. For instance, in March 2022, Evonik Industries AG, a Germany-based pharmaceutical company, launched UDRATEC SoluFlow. UDRATEC SoluFlow is a novel microparticle technology designed to improve the solubility of active medicinal components in oral medication formulations. This emulsion-based process technique overcomes solubility barriers that traditional production methods cannot. EUDRATEC SoluFlow adds to Evonik Health Care's range of oral drug delivery system solutions, which includes oral excipients like EUDRAGIT functional polymers, ready-to-fill functional capsules like EUDRACAPTM, and other technologies and services to improve medication performance.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Key Segments -

The controlled release drug delivery market covered in this report is segmented -

1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Peronal, Research, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.